-
Mashup Score: 16Liquid Biopsy to Detect Ovarian Cancer on the Horizon - 3 day(s) ago
Abstract: Researchers have successfully developed a liquid biopsy ovarian cancer assay. Known as DELPHI-protein, the assay uses AI to cross reference the presence of cell-free DNA fragmentomes and biomarkers in patients’ blood. The test generates results that have more than twice the positive predictive value as currently available ovarian cancer tests and produces almost no false positive results.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4A framework for assessing interactions for risk stratification models: the example of ovarian cancer - 9 day(s) ago
Abstract. Generally, risk stratification models for cancer use effect estimates from risk/protective factor analyses that have not assessed potential inter
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-Resistant Ovarian Cancer - Merck.com - 15 day(s) ago
BASKING RIDGE, N.J. & RAHWAY, N.J., April 3, 2024 – Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 Phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. The Phase 2 portion of the trial will be conducted to identify the dose of raludotatug deruxtecan to be used in the Phase 3 part of the trial, which will evaluate raludotatug deruxtecan versus investigator’s choice of chemotherapy. Raludotatug deruxtecan is an investigational specifically engineered potential first-in-class CDH6 directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed with Merck. Between 70% and 80% of patients diagnosed with advanced ovarian cancer will experience disease progression following standard treatment with
Source: www.merck.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 7
Abstract. High-grade serous ovarian carcinoma (HGSOC) is the deadliest subtype of ovarian cancer. While PARP inhibitors (PARPi) have transformed the care of advanced HGSOC, PARPi resistance poses a major limitation to their clinical utility. DNA damage checkpoint signaling via ATR kinase can counteract PARPi-induced replication stress, making ATR an attractive therapeutic target in PARPi-resistant tumors. However, ATR inhibitor (ATRi) efficacy in the clinic is low, emphasizing the need for suitable combination treatments. In this issue of Cancer Research, Huang and colleagues uncovered cytotoxic synergism between inhibition of the PI3K/AKT pathway and ATR based on high-throughput screening for ATRi drug combinations in PARPi-resistant HGSOC cells. Dual inhibition of ATR and AKT resulted in aberrant replication stress and cell death, which was attributed in part to impaired resolution of replication-stalling RNA:DNA hybrids (R loops). The authors identified the DNA/RNA helicase DHX9 as
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Our findings indicate that combining cell-free DNA methylation analysis in three genetic regions with CA125 may improve the sensitivity of ovarian cancer detection in high-risk women. Women with a po…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
In this CancerSpeak episode, CANCER Editorial Board Member Dr. Linda Duska is joined by Dr. Melissa Lumish and Dr. William Tew to discuss the latest advances in epithelial ovarian cancer research, including results demonstrating improved survival and outcomes of negative trials. Annie Ellis, a 19-year ovarian cancer survivor and research advocate, also joins to provide a patient perspective. Access the article at //bit.ly/OvarianCATopAdvances Music: Ivymusic from Pixabay
Source: cancerspeak.podbean.comCategories: General Medicine News, Onc News and JournalsTweet-
In a new episode of CancerSpeak, Dr. @LumishMelissa and Dr. William Tew from @MSKCancerCenter share their expertise on recent breakthroughs and future opportunities in #OvarianCancer treatment. Hear a clip from Dr. Tew below and listen to the full episode: https://t.co/HsEKWP13qw https://t.co/PM7rKQB7dM
-
-
Mashup Score: 7
After a shock diagnosis and starting chemotherapy last month, Chloe Ball’s only priority is to survive for her 1-year-old baby.
Source: www.newsweek.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36New surgical method for ovarian cancer lights up lesions - Mayo Clinic Comprehensive Cancer Center Blog - 2 month(s) ago
Study results show fluorescence-guided surgery, which uses fluorescence imaging to light up cancerous tissue, helps surgeons remove more ovarian cancer.
Source: cancerblog.mayoclinic.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 15Research identifies predictor of outcomes, chemoresistance for ovarian cancer patients - 2 month(s) ago
Newly published research from an international consortium led by the University of Minnesota’s Masonic Cancer Center has the potential to transform the landscape of ovarian cancer treatment.
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Cancer: Vol 130, No 6 - 2 month(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Onc News and JournalsTweet
News— Liquid Biopsy to Detect #OvarianCancer on the Horizon. https://t.co/vRUIWO13ka https://t.co/dPDTmXWO03